Clinical outcomes of 1,478 danaparoid treatment case reports for HIT (involving 1,418
patients) treated between 1982 and mid-2004 are analysed. Treatment in 1,291 episodes …

Background: Patients with heparin‐induced thrombocytopenia (HIT)(with or without
thrombosis) require alternative anticoagulation because of their extreme risk of new …

Synopsis Danaparoid, a low molecular weight heparinoid consisting of a mixture of heparan,
dermatan and chondroitin sulfates, has well established antithrombotic activity. The drug has …

Purpose Danaparoid is a safe and effective drug for the treatment of heparin-induced
thrombocytopenia (HIT). We describe an uncommon complication: danaparoid cross …

Heparin-induced thrombocytopenia (HIT) is a hypercoagulable syndrome strongly
associated with thrombosis that is usually treated with drugs that inhibit factor Xa …

Aim: To compare clinical outcomes in a randomised comparison of treatment with
danaparoid sodium (a heparinoid), or dextran 70, for heparin-induced thrombocytopaenia …

Objective To evaluate the effectiveness and the safety of danaparoid sodium in the treatment
of critically ill patients with standard unfractionated heparin-induced thrombocytopenia (HIT) …

INTRODUCTION When a diagnosis of heparin-induced thrombocytopenia (HIT) is made,
cessation of heparin is mandatory. Thereafter, an alternative anticoagulant is usually …

BACKGROUND: Prognostic factors for unfavorable clinical outcome in patients with heparin-
induced thrombocytopenia (HIT) are largely unknown. DESIGN AND METHODS: In this …

INTRODUCTION: Randomized controlled trials evaluating treatment of acute, transient, but
uncommon diseases are difficult to perform. The prothrombotic adverse drug reaction …